SCHEMBL7224610

SCHEMBL7224610

Fc1ccc(C(=C2CCCCN2)c2ccc(F)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
OPRD1 P41143 1/20 0.36
ACHE P22303 1/20 0.36
PARP1 P09874 1/20 0.35
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
AURKA O14965 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7496643 0.93 RAB9A (0.47) KDM4ERAB9ANPC1SMN1; SMN2HPGD
SCHEMBL7328025 0.93 RAB9A (0.47) KDM4ERAB9ANPC1SMN1; SMN2HPGD
SCHEMBL5764963 0.81 NPC1 (0.54) RAB9ANPC1SMN1; SMN2HPGDOPRD1
Hydrochloric Acid SCHEMBL10749720 0.79 NPC1 (0.53) RAB9ANPC1SMN1; SMN2HPGDOPRD1
SCHEMBL8911057 0.71 ACHE (0.33) KDM4ERAB9ANPC1ACHE
SCHEMBL2539292 0.67 OPRD1 (0.65) OPRD1CES2CES1MELK
SCHEMBL31554128 0.66
SCHEMBL8911535 0.66 HPGD (0.44) RAB9ANPC1SMN1; SMN2HPGDOPRD1
SCHEMBL8366194 0.66 HPGD (0.44) RAB9ANPC1SMN1; SMN2HPGDOPRD1
SCHEMBL23832799 0.66 OPRD1 (0.44) KDM4EOPRD1CES2CES1MELK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545037-B2 Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example LES LABORATOIRES SERVIER (FR) 2003-04-08 US disclosed
US-6469011-B2 NITROGEN OXIDE YIELDING AND THROMBOXANE A2 (TXA2) AND SEROTONIN (5HT2) RECEPTOR ANTAGONIST; TREATMENT OF ATHEROTHROMBOTIC CARDIOVASCULAR DISORDERS LES LABORATOIRES SERVIER (FR) 2002-10-22 US disclosed
US-20020137742-A1 Benzenesulfonamide compounds LAVIELLE GILBERT (FR) 2002-09-26 US disclosed
EP-1118610-B1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2002-08-21 EP disclosed
US-20010009915-A1 New benzenesulfonamide compounds LES LABORATOIRES SERVIER (FR) 2001-07-26 US disclosed
EP-1118610-A1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009915-A1 New benzenesulfonamide compounds CNR1, CNR2, HTR1A KDM4E 2862/4885RAB9A 3300/4885NPC1 2907/4885
US-20020137742-A1 Benzenesulfonamide compounds CNR1, CNR2, HTR1A KDM4E 2685/4885RAB9A 3482/4885NPC1 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.